Rhythm Pharmaceuticals, Inc.2024财年第三财季实现净利润-43.64百万美元，同比增加1.18%

市场透视2024-11-11

11月11日，Rhythm Pharmaceuticals, Inc.（RYTM.US）公布财报，公告显示公司2024财年第三财季净利润为-43.64百万美元，同比增加1.18%；其中营业收入为33.25百万美元，同比增加47.78%，每股基本收益为-0.73美元。从资产负债表来看，Rhythm Pharmaceuticals, Inc.（RYTM.US）总负债3.52亿美元，其中短期债务0.00...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482397267?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-11 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482397267","market":"us","top_or_hot":-1,"title":"Rhythm Pharmaceuticals, Inc.2024财年第三财季实现净利润-43.64百万美元，同比增加1.18%","media":"市场透视","content":"<div>\n<p>11月11日，Rhythm Pharmaceuticals, Inc.（RYTM.US）公布财报，公告显示公司2024财年第三财季净利润为-43.64百万美元，同比增加1.18%；其中营业收入为33.25百万美元，同比增加47.78%，每股基本收益为-0.73美元。从资产负债表来看，Rhythm Pharmaceuticals, Inc.（RYTM.US）总负债3.52亿美元，其中短期债务0.00...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000228abb3637d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Pharmaceuticals, Inc.2024财年第三财季实现净利润-43.64百万美元，同比增加1.18%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Pharmaceuticals, Inc.2024财年第三财季实现净利润-43.64百万美元，同比增加1.18%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000228abb3637d&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月11日，Rhythm Pharmaceuticals, Inc.（RYTM.US）公布财报，公告显示公司2024财年第三财季净利润为-43.64百万美元，同比增加1.18%；其中营业收入为33.25百万美元，同比增加47.78%，每股基本收益为-0.73美元。从资产负债表来看，Rhythm Pharmaceuticals, Inc.（RYTM.US）总负债3.52亿美元，其中短期债务0.00...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000228abb3637d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000228abb3637d&s=b","article_id":"2482397267","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000228abb3637d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482397267","pubTimestamp":1731254501,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月11日，Rhythm Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-43.64百万美元，同比增加1.18%；其中营业收入为33.25百万美元，同比增加47.78%，每股基本收益为-0.73美元。机构评级：截至2024年11月11日，当前有11家机构对Rhythm Pharmaceuticals, Inc.目标价做出预测，其中目标均价为70.27美元，其中最低目标价为58.00美元，最高目标价为84.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"Rhythm Pharmaceuticals, Inc. achieved net profit of-US $43.64 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 1.18%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":0.9},"content_text":"11月11日，Rhythm Pharmaceuticals, Inc.（RYTM.US）公布财报，公告显示公司2024财年第三财季净利润为-43.64百万美元，同比增加1.18%；其中营业收入为33.25百万美元，同比增加47.78%，每股基本收益为-0.73美元。从资产负债表来看，Rhythm Pharmaceuticals, Inc.（RYTM.US）总负债3.52亿美元，其中短期债务0.00美元，资产负债比为1.04，流动比率为0.04。机构评级：截至2024年11月11日，当前有11家机构对Rhythm Pharmaceuticals, Inc.目标价做出预测，其中目标均价为70.27美元，其中最低目标价为58.00美元，最高目标价为84.00美元。公司简介：Rhythm Pharmaceuticals Inc 是一家生物制药公司，从事罕见病治疗方法的开发和商业化。公司专注于开发和商业化用于治疗胃肠道疾病和导致代谢紊乱的遗传缺陷的肽疗法。该公司的候选产品是setmelanotide (RM 493)，这是一种有效的黑素皮质素4或MC4受体激动剂，用于治疗由MC4通路缺陷引起的罕见遗传性肥胖疾病。从地理上看，该公司的收入来自美国、德国和其他国家，其中大部分来自美国。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482397267","isCrawlerRequest":true}